Investors
Company Profile
Founded in November 2012, ObsEva is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. We believe our expertise has led to the development of new and innovative therapies that have the potential to improve patient outcomes in reproductive health.
Financial Reports
Investor presentations
Investor Presentation Jefferies Virtual London Healthcare Conference November 18, 2020
Results: PROLONG Proof-of-Concept Trial of Ebopiprant (OBE022) for Treatment of Preterm Labor
Corporate Deck September 2020
Corporate Deck August 2020
Investor Presentation Conference Call 6th July, 2020
Investor Presentation Jefferies Virtual Healthcare Conference June 3rd, 2020
Investor Presentation May 2020
JP Morgan Healthcare Conference, San Francisco, 15th January 2020
Press Releases
ObsEva SA to present at The International Society of Gynecological Endocrinology 19th World Congress – virtual edition, December 2-5, 2020
press release
December 1, 2020
Geneva, Switzerland and Boston, MA – December 1, 2020 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical…
Read moreObsEva SA Submits Marketing Authorization Application to the European Medicines Agency for YSELTY® (linzagolix) for the Treatment of Women with Uterine Fibroids
press release
November 24, 2020
If approved, linzagolix will be the only GnRH antagonist with flexible dose regimen options for the management of uterine…
Read moreObsEva SA Reports Positive Topline Results of the PROLONG Proof-of-Concept Trial of Ebopiprant (OBE022) for Treatment of Preterm Labor
press release
November 16, 2020
Over 50% reduction of pre-term delivery within 48hrs of treatment in singleton pregnancy Maternal, fetal and neonatal safety comparable to…
Read moreGeneral Meetings
ObsEva Annual General Meeting 2020
June 9, 2020
ObsEva Annual General Meeting 2019
May 8, 2019
Upcoming Events
ObsEva SA hosts live symposium at the SEUD Online Week on Thursday November 5, 2020
Event
December 22, 2020
ObsEva SA to present at The International Society of Gynecological Endocrinology 19th World Congress – virtual edition, December 2-5, 2020
Event
December 6, 2020
Stock Information
Latest Press Release
ObsEva SA to present at The International Society of Gynecological Endocrinology 19th World Congress – virtual edition, December 2-5, 2020
Geneva, Switzerland and Boston, MA – December 1, 2020 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical…
Read moreInvestor Contact
Media Contact
Media Switzerland & Europe
Shauna Dillon
+41 (0)22 552 1550 Office
+41 79 360 3533 Mobile
Media United States
Shauna Dillon
+41 (0)22 552 1550 Office
+41 (0)79 360 3533 Mobile
Contacts
Media Switzerland & Europe
Shauna Dillon
+41 (0)22 552 1550 Office
+41 79 360 3533 Mobile
Media United States
Shauna Dillon
+41 (0)22 552 1550 Office
+41 (0)79 360 3533 Mobile
Sign up for news
